Ryvu Therapeutics S.A. (WSE: RVU)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	176.47	57.94	101.92	83.24	136.22	72.11
Short-Term Investments	71.08	175.73	0.53	4.99	24.97	-
Cash & Short-Term Investments	247.55	233.67	102.45	88.23	161.19	72.11
Cash Growth	-4.22%	128.10%	16.11%	-45.26%	123.54%	-23.98%
Accounts Receivable	12.39	9.19	1.05	5.94	2.2	1.65
Other Receivables	11.65	23.65	258.85	5.8	5.75	13.39
Receivables	24.04	32.84	259.89	11.74	7.95	15.04
Inventory	2.7	2.12	1.76	1.96	1.68	1.59
Prepaid Expenses	-	-	2.35	1.63	0.58	0.3
Other Current Assets	21.47	9.77	1.48	0.69	0.98	0.95
Total Current Assets	295.76	278.39	367.93	104.25	172.36	89.98
Property, Plant & Equipment	74.15	77.56	82.22	91.18	91.16	66.19
Long-Term Investments	17.83	34.37	20.48	29.4	29.12	23.75
Other Intangible Assets	7.9	6.34	4.28	3.04	2.32	2.92
Long-Term Deferred Tax Assets	-	-	-	0.33	0.59	0.7
Other Long-Term Assets	7.54	6.55	0.08	0.6	0.09	0.09
Total Assets	403.18	403.2	474.98	228.81	295.64	183.63
Accounts Payable	28.29	23.14	12.58	11.69	6.26	13.35
Accrued Expenses	11.33	12.22	11.7	4.86	5.31	3.41
Short-Term Debt	0.15	0.13	0.06	0.02	0	0.01
Current Portion of Long-Term Debt	-	-	0.81	0.81	0.81	0.81
Current Portion of Leases	0.22	0.41	1.03	1.92	2.27	2.47
Current Income Taxes Payable	-	-	-	5.46	-	-
Current Unearned Revenue	25.87	31.53	16.71	8.95	14.56	2.3
Other Current Liabilities	31.66	2.27	1.93	2.5	4.6	8.26
Total Current Liabilities	97.52	69.7	44.81	36.2	33.81	30.62
Long-Term Debt	80.37	8.85	9.9	8.86	1.55	2.36
Long-Term Leases	0.2	0.37	0.87	1.58	2.77	3.56
Long-Term Unearned Revenue	46.8	64.26	75.8	20.26	27.5	21.18
Long-Term Deferred Tax Liabilities	0.07	-	-	0.44	6.04	5.14
Other Long-Term Liabilities	0	-	0.06	0.06	-	-
Total Liabilities	225.43	143.61	131.59	67.51	71.92	63.05
Common Stock	9.25	9.25	7.34	7.34	7.34	6.39
Additional Paid-In Capital	519.75	519.75	279.06	279.06	279.06	145.19
Retained Earnings	-76.39	-0.01	92.1	175.88	261.54	293.23
Comprehensive Income & Other	-274.85	-269.39	-35.12	-300.99	-324.22	-324.22
Total Common Equity	177.75	259.59	343.39	161.3	223.72	120.58
Shareholders' Equity	177.75	259.59	343.39	161.3	223.72	120.58
Total Liabilities & Equity	403.18	403.2	474.98	228.81	295.64	183.63
Total Debt	80.94	9.76	12.67	13.19	7.41	9.22
Net Cash (Debt)	166.61	223.91	89.77	75.04	153.78	62.89
Net Cash Growth	-32.62%	149.42%	19.63%	-51.20%	144.52%	-27.48%
Net Cash Per Share	7.21	9.78	4.89	4.09	9.17	3.94
Filing Date Shares Outstanding	23.12	23.12	23.12	18.36	18.36	15.97
Total Common Shares Outstanding	23.12	23.12	23.12	18.36	18.36	15.97
Working Capital	198.24	208.69	323.12	68.05	138.55	59.36
Book Value Per Share	7.69	11.23	14.85	8.79	12.19	7.55
Tangible Book Value	169.85	253.26	339.11	158.26	221.4	117.66
Tangible Book Value Per Share	7.35	10.95	14.67	8.62	12.06	7.37
Land	-	7.47	7.47	7.47	7.47	7.47
Buildings	-	52.2	52.15	53	48.33	1.89
Machinery	-	15.38	14.15	13.8	13.11	1.94
Construction In Progress	-	-	-	0.61	4.58	36.94

Source: S&P Capital IQ. Standard template. Financial Sources.